NTRK1 and renal cell carcinoma: After excluding compounds that have not yet been widely used in clinical, sunitinib, a receptor tyrosine kinase inhibitor and chemotherapeutic agent used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST), was considered a potential drug of T2D.